Laser in situ Keratomileusis for the Correction of Hyperopia From +1.25 to +5.00 Diopters With the Technolas Keracor 117C Laser

Femtosecond-LASIK outcomes using the VisuMax®-MEL® 80 platform for hyperopia and hyperopic astigmatism refractive surgery

The present study evaluated the efficacy, the safety and the predictability of the Femtosecond laser-assisted in situ keratomileusis (Femto-LASIK) procedure for hyperopia and hyperopic astigmatism. We retrospectively analyzed the postoperative 12-month evolution of 593 eyes with hyperopia and hyperopic astigmatism that underwent Femto-LASIK treatment. The procedure was predictable and effective. No eye lost 2 lines of corrected distance visual acuity (CDVA), demonstrating a safety profile of the procedure. Nine percent of the eyes gained at least one line of CDVA. The accuracy of the spherical equivalent after 12 months was 74% within ±1.0 diopter (D) of emmetropia. The refractive outcomes were stable during the follow-up period. There were no significant complications during the procedure. Femto-LASIK using the VisuMax^®-MEL^® 80 platform was demonstrated to be a suitable option to correct selected cases of hyperopia and hyperopic astigmatism. A longer follow-up period is required to better assess the refractive results and to detect any further regression.

Laser in situ keratomileusis for high hyperopia (>5.0 diopters) using optimized aspheric profiles: efficacy and safety

PURPOSE

To evaluate the clinical outcomes of laser in situ keratomileusis (LASIK) for high hyperopia using an excimer laser and optimized aspheric profiles.

SETTING

Vissum Corporation and Miguel Hernández University, Alicante, Spain, and Research Institute of Ophthalmology, Giza, Egypt.

DESIGN

Case series.

METHODS

Eyes of patients with high hyperopia or hyperopic astigmatism (spherical equivalent [SE] ≥ 5.64 diopters [D]) had uneventful LASIK with an aspheric optimized ablation profile centered on the corneal vertex using an Amaris 500 kHz excimer laser and a femtosecond platform for flap creation with a temporal hinge.

RESULTS

There was a significant improvement in uncorrected distance visual acuity 3 months postoperatively (P<.01), with no significant changes afterward (P=.72). At 6 months, the corrected distance visual acuity (CDVA) remained unchanged or improved in 90.48% of eyes; 2 eyes (9.52%) lost 2 lines of logMAR CDVA. The postoperative SE was within ± 0.50 D of emmetropia in 70.37% of eyes. The LASIK enhancement rate at the end of the follow-up was 29.4%. Significant induction of corneal primary spherical aberration and coma was found with 6.0 mm pupils (P<.01). The safety index was 0.94 and the efficacy index, 0.85.

CONCLUSION

Laser in situ keratomileusis for high hyperopia using optimized aspheric profiles requires further improvement in terms of safety but was still an effective and a predictable procedure.

One-year results of excimer laser in situ keratomileusis for hyperopia

PURPOSE

To evaluate the visual and refractive results of hyperopic LASIK.

SETTING

Clínica Baviera Instituto Oftalmológico Europeo, Madrid, Spain.

METHODS

This retrospective consecutive noncomparative observational study evaluated hyperopic LASIK results over 1 year. Outcomes included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), cycloplegic refraction, and corneal topography. Surgery was performed using an MEL 80-G excimer laser. Results were analyzed by preoperative spherical equivalent (SE) (Group 1: <or=+3.50 diopters [D]; Group 2: >or=+3.60 D).

RESULTS

The mean UDVA improved from 0.50 +/- 0.3 (SD) to 0.90 +/- 0.2 in Group 1 and from 0.50 +/- 0.3 to 0.80 +/- 0.2 in Group 2 and the mean CDVA, from 0.86 +/- 0.2 to 0.93 +/- 0.1 and from 0.80 +/- 0.2 to 0.90 +/- 0.2, respectively. The mean cycloplegic SE improved from +2. 5+/- 0.8 to +0.1 +/- 0.5 in Group 1 and from +4.5 +/- 0.6 to +0.4 +/- 0.6 in Group 2; 70.9% of eyes and 63.3% of eyes, respectively, were within +/-0.50 D of emmetropia. Postoperatively, 92.8% of eyes in Group 1 and 87.8% in Group 2 maintained or gained 1 or more lines of CDVA; 1.7% and 4.0%, respectively, lost 2 or more lines. The safety index was 1.1 in both groups and the efficacy index, 1.01 in Group 1 and 0.98 in Group 2. The enhancement rate was 20.0% and 18.4%, respectively.

CONCLUSION

Excimer laser LASIK was safe and effective for treating hyperopia up to +6.25 D with no further loss of CDVA lines after enhancement.

Laser in situ keratomileusis for mixed astigmatism using a modified formula for bitoric ablation

PURPOSE

To evaluate the results of treatment of mixed astigmatism with laser in situ keratomileusis (LASIK) by means of a modified Chayet formula for bitoric ablation and personalized nomogram calculations.

METHODS

A retrospective study was conducted in 19 consecutive eyes of 13 patients who underwent LASIK treatment of mixed astigmatism with a mean sphere of +1.63-/+1.23 D and a mean cylinder of -3.55-/+1.17 D. The authors used the Schwind ESIRIS Laser platform. The ablation was shifted from the pupil center to the vertex normal of the cornea.

RESULTS

Three months postoperatively, the mean sphere was 0.08-/+0.24 D and the mean astigmatism -0.45-/+0.31 D. At 3 months, an uncorrected visual acuity (UCVA) of 20/50 or better could be found in 100% of the eyes, and of 20/25 or better in 59%. All eyes were within -/+0.5 D spherical equivalent (SE) at 3, 6, and 12 months. No eye lost more than one line of best spectacle-corrected visual acuity (BSCVA). Postoperatively, the corneal wavefront showed a reduction of spherical aberrations and coma, which were analyzed at 4 and 6 mm pupil diameter. The postoperative higher-order aberrations decreased at 4 mm and increased at 6 mm pupil sizes after surgery.

CONCLUSIONS

Modified bitoric treatment with the Schwind ESIRIS laser showed an excellent postoperative UCVA and BSCVA with applying external nomogram adjustments. The method demonstrated good predictability, safety, and effectiveness in the treatment of mixed astigmatism.

Advances in technologies for laser-assisted in situ keratomileusis (LASIK) surgery

Laser-assisted in situ keratomileusis (LASIK) has become the most widely used form of refractive surgery today. The objective of this surgical technique is to modify the anterior corneal shape by ablating tissue from the stroma by means of the excimer laser after creating a hinged corneal flap. This way, we are able to change the refractive status of the patient, providing better unaided vision. Continuous improvements in the original technique have made the surgical procedure safer, more accurate and repeatable. These progressions are due to the development of novel technologies that are the responsible for new surgical instrumentation, which makes the surgical procedure easier for the surgeon, and better excimer laser ablation algorithms, which increase the optical quality of the ablation and thus the safety of the vision correction procedure. This article aims to describe the more relevant advances in LASIK that have played an important role in the spread and popularity of this technique.

Hyperopic LASIK With Esiris/Schwind Technology

PURPOSE

To investigate the refractive and visual outcomes of hyperopic LASIK using Esiris/Schwind technology.

METHODS

This retrospective non-comparative observational study included 106 eyes (65 patients) operated with the Esiris/Schwind laser for hyperopia. Eyes were divided into two groups: group 1, < or = +3.99 diopters (D) and group 2, > or = +4.0 D (up to +7.0 D). Visual outcome for distance and near uncorrected (UCVA) and best spectacle-corrected visual acuities (BSCVA) (decimal values), cycloplegic refraction, keratometry (K), pachymetry, and complications were evaluated.

RESULTS

In group 1, mean UCVA was 0.4 +/- 0.1 preoperatively and 0.8 +/- 0.2 6 months postoperatively. Mean BSCVA was 0.9 +/- 0.1 preoperatively and 0.9 +/- 0.1 6 months postoperatively. Safety index was 1.1 and efficacy index was 0.97. Mean spherical equivalent refraction was +2.33 +/- 0.9 D preoperatively and +0.3 +/- 0.3 D 6 months postoperatively. Mean K reading was 43.7 +/- 1.1 D preoperatively and 45.0 +/- 1.6 D 6 months postoperatively. In group 2, mean UCVA was 0.3 +/- 0.1 preoperatively and 0.8 +/- 0.2 6 months postoperatively. Mean BSCVA was 0.9 +/- 0.1 preoperatively and 0.9 +/- 0.1 6 months postoperatively. Safety index was 0.98 and efficacy index was 0.92. Mean spherical equivalent refraction was +5.1 +/- 0.9 D preoperatively and +0.4 +/- 0.5 D 6 months postoperatively. Mean K reading was 43.1 +/- 1.6 D preoperatively and 46.0 +/- 1.4 D 6 months postoperatively. Forty-six (90.2%) of 51 eyes in group 1 and 47 (85.5%) of 55 eyes in group 2 were within +/- 0.5 D of emmetropia. At 6-month follow-up, 40 (78%) of 51 eyes in group 1 had UCVA of 20/20 compared to 41 (75%) of 51 eyes in group 2. One (2%) of 51 eyes in group 1 and 4 (7.3%) of 55 eyes in group 2 lost < or = 2 lines of BSCVA. No eye lost >2 lines of BSCVA.

CONCLUSIONS

Hyperopic LASIK with Esiris/Schwind technology is effective and safe in the correction of hyperopia up to + 7.0 D. Although a slight statistical significance was found for low hyperopia, visual and refractive results obtained in high hyperopia were encouraging.

Surgical Correction of Hyperopia

Surgical attempts to correct hyperopia have yielded varying results over the last 130 years. These techniques include the reshaping of the cornea through incisions, burns, or lamellar cuts with removal of peripheral tissue; the addition of central inlays; laser ablations; and the replacement of the crystalline lens. By examining the success of each surgical technique, the refractive surgeon may be able to make an informed decision on its indications and limitations, based on the specific patient's characteristics. Reporting the outcomes and complications of hyperopic surgery will help refine our approach to the management of an increasingly hyperopic and presbyopic population.

Laser eye surgery for refractive errors

Several laser and non-laser refractive surgical procedures have been used to modify the shape of the cornea and correct myopia, hyperopia, astigmatism, and presbyopia. Introduction of the excimer laser to reshape the cornea has resulted in remarkable developments in the correction of these refractive errors. Combined with other advanced ophthalmological instruments, laser refractive eye surgery has resulted in a substantial rise in the safety, efficacy, and predictability of surgical outcomes. Despite these advances, certain limitations and complications persist. In this review, we describe the history, preoperative assessment, surgical techniques, outcomes, and complications of laser refractive surgery.

Corneal Flap Measurements in Laser in situ Keratomileusis Using the Moria M2 Automated Microkeratome

PURPOSE

To evaluate accuracy and predictability and factors that influence the dimensions of the laser in situ keratomileusis (LASIK) corneal flap created with the Moria M2 automated microkeratome (Moria SA, Antony, France).

METHODS

The flap thickness of 454 eyes of 243 consecutive patients was measured using subtraction ultrasonic pachymetry during LASIK with the Moria M2 microkeratome head 130 designed to create a 160-microm-thick flap. Flap dimensions were evaluated and measurements were correlated with preoperative parameters. A stepwise regression analysis was used to determine the factors that influenced actual flap thickness.

RESULTS

The preoperative spherical equivalent refraction of the 454 eyes ranged from -12.125 diopters (D) to +6.25 D. Patient age ranged from 18 to 57 years (mean age: 31.3 +/- 8.8 years). Mean preoperative keratometric power K1 was 44.31 +/- 1.59 D and K2 was 43.32 +/- 1.54 D. Mean preoperative central comeal thickness was 552.4 +/- 32.5 microm (range: 466 to 665 microm). With an attempted thickness of 160 microm, the Moria M2 flap thickness ranged from 77 to 209 microm (mean: 153.3 +/- 19.0 microm). Mean horizontal flap diameter was 9.2 +/- 0.2 mm and mean hinge length 4.6 +/- 0.3 mm. Increasing flap thickness was found to correlate with increasing preoperative comeal thickness, younger patient age, and flatter preoperative keratometric power K1.

CONCLUSIONS

Although the standard deviation of the flap thickness was relatively small, remarkable individual variation was noted. Therefore, the intraoperative calculation of the remaining stromal bed is recommended. Furthermore, the consideration of central corneal thickness, patient age, and preoperative keratometry are helpful parameters to avoid too deep ablation.

Laser in situ keratomileusis for primary hyperopia

PURPOSE

To evaluate the efficacy, predictability, stability, and safety of hyperopic laser in situ keratomileusis (H-LASIK) over a 24-month period and analyze topographic changes after H-LASIK to assess topographic pseudokeratectasia (TPKE) following H-LASIK.

SETTING

Eye Institute of Utah, Salt Lake City, Utah, USA.

METHODS

This prospective study included 139 eyes of 77 patients having H-LASIK for primary hyperopia. The mean follow-up was 15.6 months +/- 7.6 (SD) (range 6 to 48 months). One hundred twenty-two eyes (88%) were followed at 1 year and 36 eyes (26%) at 24 months. Topographic pseudokeratectasia was defined as 1 or more positive keratoconus screening findings in an eye with topographic central or inferior steepening detected by the Topography Modeling System but without corneal thinning or progressive change.

RESULTS

The mean spherical equivalent manifest refraction was +2.39 +/- 0.99 diopter (D) preoperatively and -0.05 +/- 0.61 D at the last visit. Ninety-one percent of eyes were within +/-1.00 D of emmetropia and 71% of the eyes were within +/-0.50 D. Uncorrected visual acuity of 20/20 or better was present in 42%, 20/25 in 63%, and 20/40 or better in 93% of eyes. Loss of 2 lines of BSCVA occurred in 2 eyes (1.4%). In 1 eye, ischemic optic neuropathy occurred, and in another, choroidal neovascularization developed postoperatively. Topographic pseudokeratectasia was detected in 28% to 56% of eyes postoperatively. No significant difference between postoperative visual and refractive outcome, regression, or irregularity was found between the eyes with or without TPKE.

CONCLUSION

Hyperopic LASIK appears to be an effective, predictable, and safe procedure to correct low to moderate primary hyperopia. Topographic pseudokeratectasia, which was observed after H-LASIK with a keratoconus-like topographic pattern in otherwise normal eyes, may represent a relatively static condition.

5-year follow-up of LASIK for hyperopia

PURPOSE

To assess the long-term efficacy and stability of LASIK for hyperopia (+0.75 to +7.00 diopters [D]).

DESIGN

Retrospective follow-up study of a previous phase III multicenter clinical trial (unpublished data).

PARTICIPANTS

Patients who had been treated for hyperopia (33 individuals, 47 eyes) attended follow-up 5 years after surgery. The preoperative mean spherical equivalent at the spectacle plane was +3.58 D (range, +0.75 to 7.00 D), and the attempted mean spherical correction at the corneal plane was +3.18 D (range, +1.00 to +6.00 D).

INTERVENTION

Treatments were performed using a Moria LSK One microkeratome and a Summit Technology SVS Apex Plus excimer laser fitted with an Axicon.

MAIN OUTCOME MEASURES

Manifest refraction, uncorrected visual acuity, best spectacle-corrected visual acuity, corneal transparency, complications, and patient satisfaction were recorded.

RESULTS

At 5 years, for treatments between +1.00 to +3.00 D, 71.0% of eyes were within +/-1.00 D of the intended correction, and for treatments between +3.5 to +6.0 D, 37.5% of eyes were within +/-1.00 D of intended correction. From 12 to 54 months after surgery for all patients, there was a hyperopic shift of +0.53 D (range, -0.13 to +3.13 D), with 51.1% of eyes experiencing an increase of +0.50 D or more and 27.7% of eyes showing a hyperopic shift of more than +1.00 D. This hyperopic shift was +0.67 D (range, 0 to +1.125 D) for patients younger than 40 years of age and +0.44 D (range, -1.33 to +1.50 D) for patients between 43 and 55 years of age.

CONCLUSIONS

LASIK was moderately effective for the correction of low degrees of hyperopia. However, there was regression throughout the 5-year follow-up that was greater than would be expected as a result of aging. Long-term stability of hyperopic LASIK refractive corrections, therefore, is uncertain.

Hyperopic Laser in situ Keratomileusis With 5.5-, 6.5-, and 7.0-mm Optical Zones

PURPOSE

To evaluate the results of laser in situ keratomileusis (LASIK) for the correction of hyperopia and hyperopic astigmatism using a large 7.0-mm optical zone and to compare them with treatments using a 5.5- and 6.5-mm optical zone.

METHODS

One hundred sixty-one eyes of 89 patients with a mean preoperative spherical equivalent refraction of +2.44 +/- 1.32 diopters (D) (range: +0.00 to +5.62 D, cylinder 5.25 to 0.00 D) were treated for hyperopia and hyperopic astigmatism using a 7.0-mm optical zone and were analyzed retrospectively. Postoperatively, patients were examined after 1 day, 1 week, 1 month, 3 months, and 1 year. Eyes treated previously at the same center by the same surgeons with 5.5- and 6.5-mm optical zone applications were used as controls. All treatments were performed with the Nidek EC 5000 CXII excimer laser system (Nidek, Gamagori, Japan). A nasal hinged flap was created using the Nidek MK 2000 microkeratome in all cases.

RESULTS

The mean postoperative spherical equivalent refraction after 1 month (n=89) was +0.12 +/- 0.72 D (range: -1.75 to +2.75 D), +0.13 +/- 0.74 D (range: -1.88 to +1.62 D) at 3 months (n=70), and +0.20 +/- 0.69 D (range: -1.62 to +1.12 D) at 1 year (n=33). Regression between 1 month and 1 year was 0.08 D in the 7.0-mm optical zone group. Regression was 0.25 D in the 5.5-mm group and 0.02 D in the 6.5-mm optical zone group between 1 month and 1 year. In both the 5.5- and 6.5-mm optical zone groups, 13% of eyes lost one line in visual acuity (2% in the 7.0-mm optical zone group). The gain of one or more lines in visual acuity was 19% in the 5.5-mm group, 17% in the 6.5-mm group, and 27% in the 7.0-mm optical zone group. All data represent primary cases without retreatment.

CONCLUSIONS

Increasing the optical zone size from 5.5 mm to 6.5 mm and to 7.0 mm seems to improve refractive results, stability, and safety of hyperopic and hyperopic-astigmatic LASIK treatments. Although some hyperopic and astigmatic eyes are endangered by loss of lines in best spectacle-corrected visual acuity, more eyes gain one or more lines.

LASIK for hyperopia, hyperopic astigmatism, and mixed astigmatism

OBJECTIVE

To describe LASIK for hyperopia, hyperopia with astigmatism, and mixed astigmatism and to examine the evidence to answer questions about the safety and efficacy of the procedure.

METHODS

A literature search conducted for the years 1968 to 2002 retrieved 118 citations. During review and preparation of this article, an additional 2 articles were included. The panel members selected 36 articles for the panel methodologist to review and rate according to the strength of evidence. A level I rating is assigned to properly conducted, well-designed, randomized clinical trials; a level II rating to well-designed cohort and case-control studies; and a level III rating to case series, case reports, and poorly designed prospective and retrospective studies.

RESULTS

This assessment describes 5 nonrandomized interventional trials (level II), 3 nonrandomized comparative trials (level III), and 20 noncomparative case series (level III). Additionally, 6 single-case reports (level III) were included because they reported relevant complications, and 2 theoretical analyses (level III) were also considered. This assessment does not compare studies because many variables such as range of hyperopia, follow-up periods, lasers, microkeratomes, techniques, and surgeon experience have not been controlled.

CONCLUSIONS

For low (<3 diopters [D]) to moderate (3-5 D) hyperopia, results from published studies (levels II and III evidence) have shown that LASIK is effective and predictable in achieving very good to excellent uncorrected visual acuity, achieving postoperative refractions within 1 D of emmetropia, and is safe in terms of minimal loss of best-corrected spectacle vision. Although there are fewer data for hyperopic astigmatism, the results available seem to mirror the data for low to moderate hyperopia (levels II and III evidence). The postoperative results for both uncorrected vision and safety are less compelling, as greater amounts of hyperopia are treated (>4 to 5 D). Utilizing hyperopic LASIK for the treatment of consecutive hyperopia and astigmatism is also effective, although the ability to reduce hyperopic astigmatism after radial keratotomy is limited. Although a variety of ablation profiles can be used to treat mixed astigmatism, very good visual results have been reported (levels II and III evidence). Serious adverse complications leading to permanent visual loss are possible but, fortunately, very rare. There are insufficient data to compare one laser system with another or one ablation profile with another.

Laser in situ keratomileusis for hyperopia with the LADARVision 4000 with centration on the coaxially sighted corneal light reflex

PURPOSE

To analyze the visual acuity, contrast sensitivity, and target deviations in patients who had laser in situ keratomileusis (LASIK) for primary hyperopia with the ablation centered on the coaxially sighted corneal light reflex.

SETTING

University-based refractive surgery practice.

METHODS

Retrospective review comprised 37 consecutive patients (61 eyes) who had LASIK for hyperopia with the LADARVision 4000 excimer laser (Alcon Laboratories). Preoperative and 3-month postoperative visual acuity and contrast sensitivity, as well as the target deviation, were assessed for each eye. The change in best spectacle-corrected visual acuity (BSCVA), best spectacle-corrected contrast sensitivity (BSCCS), and target deviation from the intended correction were analyzed.

RESULTS

Postoperatively, the uncorrected visual acuity (UCVA) was 20/20 or better in 44.4% of eyes. The mean deviation from target was +0.25 diopter (D) +/- 0.82 (SD), with 65.6% of eyes within +/-0.50 D of target. None eye lost 2 or more lines of BSCVA. A loss of 3 or more patches of BSCCS were seen in 6.6% of the eyes and a loss of 4 or more patches, in 1.6%.

CONCLUSION

Hyperopic LASIK with LADARVision 4000 with the ablation zone centered on the coaxially sighted corneal light reflex did not adversely affect BSCVA and BSCCS.

Five-year Follow-up of Laser in situ Keratomileusis for Hyperopia Using the Technolas Keracor 117C Excimer Laser

PURPOSE

To evaluate safety, predictability, efficiency, and long-term stability of laser in situ keratomileusis (LASIK) for spherical hyperopia.

METHODS

This study was a retrospective 5-year analysis of 67 patients (125 eyes) who had LASIK for spherical hyperopia; preoperative mean manifest spherical equivalent refraction was +3.84+/-1.13 D (range +1.00 to +6.50 D) and mean astigmatism was 0.37+/-0.27 D (range 0 to 1.00 D). Preoperative spherical equivalent refraction for the low hyperopia group was +1.00 to +2.75 D; medium hyperopia group, +3.00 to +4.25 D, and high hyperopia group, +4.50 to +6.50 D. All surgeries were performed using the scanning Chiron Technolas Keracor 117C excimer laser. Uncorrected and best spectacle-corrected visual acuity, predictability, long-term stability of refraction, and complications were analyzed.

RESULTS

At 5 years after hyperopic LASIK, mean spherical equivalent refraction for the low hyperopia group was +0.48D+/-0.79 D; medium hyperopia group, +1.52+/-1.45 D; high hyperopia group C, +3.39+/-1.98 D. The percentage of eyes with a spherical equivalent refraction within +/-0.50 D of emmetropia for the low hyperopia group was 63% (37 eyes); medium hyperopia group, 42% (20 eyes); high hyperopia group, 22% (4 eyes). Eyes with chronic dry eye symptoms had a mean difference in spherical equivalent refraction from target refraction of +1.43 D compared with +0.84 D for eyes without dry eye symptoms. Five eyes (4%) lost 2 lines of BSCVA at 5 years.

CONCLUSION

LASIK was safe, effective, and stable for primary hyperopia between +1.00 and +3.00 D. Higher amounts of hyperopia had poor long-term stability, especially eyes with more than +4.25 D. Chronic dry eye symptoms were associated with regression over time.

Two-year results of conductive keratoplasty for the correction of low to moderate hyperopia

PURPOSE

To evaluate the 2-year postoperative safety, efficacy, predictability, and stability results of conductive keratoplasty (CK) to correct low to moderate hyperopia.

SETTING

Department of Ophthalmology, Stanford University Medical Center, Stanford, California, USA.

METHODS

In a prospective nonrandomized noncontrolled trial, 25 eyes of 14 patients with +0.75 to +3.00 diopters (D) of hyperopia and </=0.75 D of cylinder were treated with CK. Low-energy, radio-frequency current was applied to the peripheral corneal stroma through a probe inserted at 8 to 32 treatment spots. An early nomogram was used in 2 eyes, and a current nomogram was used in 23 eyes; the intended refraction was plano. The 23 eyes treated with the current nomogram were analyzed for efficacy, predictability, and stability. All 25 eyes were included in the safety and patient-satisfaction analyses.

RESULTS

Preoperatively, the mean manifest refraction spherical equivalent (MRSE) in the 23 current-nomogram eyes was +1.55 D. At 2 years, the uncorrected visual acuity was 20/20 or better in 64% of eyes and 20/40 or better in 95%. The MRSE was within +/-0.50 D in 64% of eyes, within +/-1.00 D in 91%, and within +/-2.00 D in 100%. No eye lost more than 1 line of best spectacle-corrected visual acuity or had an induced cylinder greater than 0.75 D. The mean MRSE of the cohort with all follow-ups was +0.48 D, which reflected a 29% regression from the intended plano and 43% regression from the 1-month postoperative overcorrection. The rate of regression appeared to be low and decreasing, +0.024 D per month between 12 and 24 months. A patient survey revealed improved quality of vision and a high level of satisfaction.

CONCLUSIONS

Conductive keratoplasty appeared to be safe, effective, and predictable for correcting low to moderate hyperopia. Mild hyperopic regression was observed; however, the rate of regression indicated by the mean change in MRSE per month was low and decreased over the 2-year follow-up. Longer follow-up may be necessary to further characterize the refractive stability of CK.

Long-term evaluation of hyperopic laser in situ keratomileusis

PURPOSE

To evaluate the efficacy, safety, and predictability of hyperopic laser in situ keratomileusis (H-LASIK).

SETTING

Departments of Ophthalmology, Hadassah University Hospital, Jerusalem, and Assaf Harofeh Medical Center, Zerifin, Israel.

METHODS

This prospective noncomparative case series studied the results of H-LASIK in the first 92 consecutive eyes of 50 patients with up to +10.25 diopters (D) of hyperopia. For analysis, the patients were divided into 3 groups based on preoperative hyperopia: low hyperopia (< +3.00 D), moderate hyperopia (> or = +3.00 to 6.00 D), and high hyperopia (> or = +6.00 D).

RESULTS

Forty-two patients, 77 eyes (83.7%), were followed for at least 12 months. At 12 months, the mean manifest spherical equivalent was +0.33 +/- 0.65 D (93.1% of eyes within +/-1.0 D of the intended correction) in the low myopia group, +0.21 +/- 0.60 D (92.3% within +/-1.0 D of the intended correction) in the moderate hyperopia group, and +1.62 +/- 1.50 D (36.4% within +/-1.0 D of the intended correction) in the high hyperopia group. The uncorrected visual acuity (UCVA) was 20/40 or better in all eyes (100%), 24 eyes (92.3%), and 13 eyes (59.1%) in the low, moderate, and high hyperopia groups, respectively. Comparing the UCVA at the last examination with the best corrected visual acuity (BCVA) before surgery in all patients showed that 59 eyes (76.6%) were within +/-1 line and 18 eyes (23.4%) were within +/-2 or more lines of the preoperative BCVA. Three eyes (3.9%) in the high hyperopia group lost 2 or more lines of BCVA. Three eyes (3.9%) had flap- related complications. Eight patients (15 eyes) with a follow-up less than 12 months did not have intraoperative or postoperative complications.

CONCLUSION

Laser in situ keratomileusis was a safe, effective, and predictable procedure for hyperopia up to +6.0 D and less predictable for higher hyperopia.

Laser in situ Keratomileusis for Hyperopia and Hyperopic and Mixed Astigmatism With LADARVision Using 7 to 10-mm Ablation Diameters

PURPOSE

To evaluate the results of laser in situ keratomileusis (LASIK) performed to correct hyperopia, and hyperopic and mixed astigmatism using wider ablation diameters (optical zone diameter and overall ablation diameter) than those commonly used with the same and other lasers.

METHODS

After flap creation using an Alcon SKBM microkeratome set for a 10-mm flap diameter, 53 eyes (33 patients) with a mean spheroequivalent attempted correction of +2.34 +/- 2.09 D underwent LASIK (Alcon LADARVision 4000) using a 7-mm optical zone diameter and a 3-mm transition zone for an overall 10-mm total ablation diameter. The nasal hinge was prevented from undesired ablation by the use of proprietary hinge protector software. Eyes were followed for 6 months after surgery.

RESULTS

Six months after surgery, mean spheical equivalent refractive error was -0.22 +/- 0.41 D. There were 79.2% of eyes within +/- 0.50 D, and 98.1% within +/- 1.00 D of intended correction. Uncorrected visual acuity of 20/20 or better was achieved by 28 eyes (53%) and 20/40 or better by 50 eyes (94.3%). No meaningful visual complaints during nighttime hours, such as haloes or glare, were subjectively reported by patients.

CONCLUSION

The use of larger ablation diameters in LASIK for hyperopia, and hyperopic and mixed astigmatism produced accurate results, early refractive stability, and good visual performance.

Update on nonexcimer laser refractive surgery technique: conductive keratoplasty

Excimer laser-based refractive surgery techniques have been the most popular forms to correct myopia, hyperopia, and astigmatism. However, development of non-excimer based refractive surgery such as thermal techniques provides a viable alternative to laser vision correction. Earlier forms of thermal techniques showed a lack of predictability and stability, resulting in the abandonment of the further development of these techniques. Recently, conductive keratoplasty, a laserless, radiofrequency-based technique, has been approved by the FDA for the correction of low to moderate hyperopia. Preliminary data showed that conductive keratoplasty seems to be safe, effective, and showed good refractive stability. This review will discuss recent studies on conductive keratoplasty technique in terms of its efficacy, safety, refractive predictability, and stability.

Histological and immunohistochemical findings after laser in situ keratomileusis in human corneas

PURPOSE

To describe histopathological and immunohistochemical findings in human corneas after myopic laser in situ keratomileusis (LASIK) followed by iatrogenic keratectasia and after hyperopic LASIK.

SETTING

Department of Ophthalmology, University of Innsbruck, Innsbruck, Austria.

METHODS

Clinical, histological, and immunohistochemical investigations were performed of 1 human cornea with iatrogenic keratectasia following myopic LASIK and 1 human cornea with irregular astigmatism and central scar formation after hyperopic LASIK. Corneal buttons were obtained during penetrating keratoplasty in both patients.

RESULTS

Histopathological examination showed thinning of the central stroma with a posterior residual thickness of 190 microm in the patient with iatrogenic keratectasia after myopic LASIK and significant midperipheral thinning in the patient who had hyperopic LASIK. However, this characteristic ablation profile of the stroma after hyperopic LASIK was partially mitigated and compensated by the epithelium, which was significantly thinned in the center and markedly thickened in the midperiphery. Traces of wound healing with minimal scar tissue were present at the flap margin after myopic and hyperopic LASIK. In a few sections of the cornea with keratectasia after myopia LASIK, only a few collagen lamellae were visible crossing between the posterior residual stroma and the superficial flap. Immunohistochemical examination revealed minimally increased staining of dermatan sulfate proteoglycan within the stroma adjacent to the interface of the microkeratome incision. Increased staining of hepatocyte growth factor was found on keratocytes/fibroblasts at the flap margin in both corneas.

CONCLUSIONS

The wound-healing response is generally poor after LASIK, which may result in significant weakening of the tensile strength of the cornea after myopic LASIK, probably due to biomechanically ineffective superficial lamella. After LASIK in patients with high hyperopia, compensatory epithelial thickening in the annular midperipheral ablation zone might be partly responsible for regression.

Conductive keratoplasty for the correction of low to moderate hyperopia: U.S. clinical trial 1-year results on 355 eyes

OBJECTIVE

To document the 1-year safety, efficacy, and stability results of 355 eyes treated in the multicenter study of conductive keratoplasty (CK) used to correct low to moderate hyperopia.

DESIGN

Nonrandomized comparative (self-controlled) trial.

PARTICIPANTS

Twenty surgeons at 13 centers performed CK on the eyes of all patients enrolled in a multicenter, 2-year, U.S. phase III clinical trial. Treated eyes had +0.75 to +3.00 diopters (D) of hyperopia and < or =0.75 D of cylinder. Patients were 40 years of age or older.

INTERVENTION

Low-energy, high-frequency current was applied directly into the peripheral corneal stroma through a delivery tip inserted at 8 to 32 treatment spots. The number of treatment spots was increased for increasing levels of hyperopia, but the amount of radiofrequency energy remained constant. Emmetropia was intended. All eyes were treated once (there were no retreatments).

MAIN OUTCOME MEASURES

Data from 355 eyes with 1 year of follow-up were analyzed for safety and stability, and data from 318 eyes were analyzed for efficacy and predictability, as well as stability and safety. All patients reported on satisfaction and quality of vision after surgery.

RESULTS

At 1 year, uncorrected visual acuity was < or =20/20 in 56%, < or =20/25 in 75%, and < or =20/40 in 92% of eyes. The manifest refractive spherical equivalent refraction was within 0.50 D in 63%, within +/-1.00 D in 89%, and within +/-2.00 D in 99%. Seven of 355 eyes lost 2 lines of best spectacle-corrected visual acuity at 1 year, but no eye lost >2 lines. One eye of 355 had induced cylinder of >2.00 D. The cycloplegic refractive spherical equivalent changed a mean of 0.25 +/- 0.50 D between months 3 and 6, 0.11 +/- 0.41 D between months 6 and 9, and 0.11 +/- 0.35 D between months 9 and 12. Refractive stability seemed to be attained by 6 months and remained stable through 12 months. Histology and confocal microscopy showed deep penetration of the treatment into the stroma. Endothelial cell counts were not changed by the treatment.

CONCLUSIONS

CK seems to be safe, effective, and stable for correcting low to moderate spherical hyperopia in patients 40 years old or older. Treatment penetration is deep and cylindrical in shape, and it does not damage the corneal endothelium. Uncorrected visual acuity, predictability, and stability are as good as or better than those obtained with other techniques used to correct hyperopia.

Conductive keratoplasty for the correction of low to moderate hyperopia: 1-year results on the first 54 eyes

OBJECTIVE

To document the 1-year postoperative clinical results of the safety, efficacy, and stability of conductive keratoplasty (CK) to correct low to moderate hyperopia.

DESIGN

Prospective, nonrandomized, self-controlled trial.

PARTICIPANTS

Five surgeons at four centers performed CK on the first 54 eyes of a multicenter, 2-year clinical trial. Treated eyes had +0.875 to +4.00 diopters (D) of hyperopia and < or =0.75 D of cylinder. The nature of this procedure was explained to all participating patients who signed informed consent forms prior to undergoing the procedure.

INTERVENTION

Low energy, high-frequency current was applied directly into the peripheral corneal stroma through a delivery tip inserted at 16 or more treatment spots. An early nomogram was used for the first 54 eyes with an intended refraction of plano.

MAIN OUTCOME MEASURES

Data from all 54 eyes were analyzed for safety and stability. A subset of 30 of the 54 eyes was found that had been treated with the appropriate number of spots with the early nomogram. These eyes were categorized as current nomogram eyes; the data for these eyes were analyzed for efficacy and predictability, as well as stability and safety. All patients reported on satisfaction and quality of vision after surgery.

RESULTS

Preoperatively, the manifest refractive spherical equivalent refraction (MRSE) of the 30 current nomogram eyes was +1.57 D. At 1 year postoperatively, uncorrected visual acuity was 20/20 or better in 57% of the eyes and 20/40 or better in 93%. The MRSE was within 0.50 D in 46%, within +/-1.00 D in 93%, and within +/-2.00 D in 100%. No eye lost > or =2 lines of best spectacle-corrected visual acuity at 1 year postoperatively nor had an induced cylinder of > or =2.00 D. The MRSE changed a mean of 0.25 D +/- 0.43 between 3 and 6 postoperative months, 0.16 D +/- 0.38 between 6 and 9 postoperative months, and 0.07 D +/- 0.38 between 9 and 12 postoperative months. Refractive stability appeared to be attained by 6 months postoperatively.

CONCLUSIONS

Conductive keratoplasty appears to be safe, effective, and stable for correcting low to moderate spherical hyperopia. Stability appeared by the 6-month follow-up visit. For the eyes treated with the current CK nomogram, uncorrected visual acuity, predictability, and stability are as good as or better than those obtained with hyperopic laser in situ keratomileusis or noncontact laser thermal keratoplasty.